Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.41 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276804 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNASIGMAR1OPRM1KMT2A | |
| SCHEMBL10277098 | 0.90 | NPY2R (0.42) | KMT2AMEN1NPY2R | |
| SCHEMBL27870537 | 0.80 | ATM (0.43) | ALDH1A1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL10063608 | 0.79 | ALDH1A1 (0.57) | ALDH1A1LMNASIGMAR1KMT2AMEN1 | |
| SCHEMBL4746240 | 0.79 | SIGMAR1 (0.60) | ALDH1A1LMNASIGMAR1OPRM1KMT2A | |
| SCHEMBL27870538 | 0.79 | CACNA1G (0.46) | NPY2R | |
| SCHEMBL27870544 | 0.77 | L3MBTL1 (0.47) | ALDH1A1SIGMAR1KMT2AMEN1 | |
| SCHEMBL18074267 | 0.77 | KMT2A (0.57) | ALDH1A1LMNASIGMAR1KMT2AMEN1 | |
| SCHEMBL2862442 | 0.74 | ALDH1A1 (0.60) | ALDH1A1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5201072 | 0.74 | SIGMAR1 (0.56) | ALDH1A1LMNASIGMAR1OPRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | CTSB, TPSAB1, PIGS | ALDH1A1 591/4885LMNA 368/4885SIGMAR1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.